Latest news with #JCR
Business Wire
3 days ago
- Business
- Business Wire
JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured in The Next Frontier, a global branded film series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. The Next Frontier series explores how biotechnology can be used effectively to address urgent challenges the world faces. As part of the series, the JCR-sponsored film tells the story of a family affected by mucopolysaccharidosis type II (MPS II, or Hunter syndrome), a rare, progressive, life-threatening lysosomal storage disorder. 'This film demonstrates the hardships and challenges that people living with MPS II face on a daily basis from the perspective of a family affected by this devastating and life-limiting disease,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are honored to participate in this important video series to shine a spotlight on MPS II and increase awareness worldwide about this debilitating rare disease for which patients desperately need new treatment options. This impactful story is a great illustration of how collaborating with patient communities drives progress. We are committed to supporting the MPS II patient community, and we look forward to advancing our investigational therapy for people living with MPS II.' The Next Frontier series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection. The series debuted at the BIO International Convention, taking place from June 16-19, 2025. Watch the JCR film here, and view the full The Next Frontier series here. About The Next Frontier Series The Next Frontier is a global branded film series presented by Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions, and it explores how biotechnology can be used effectively to address urgent challenges the world faces. The series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection and features the tools that help the public not just understand biotech but believe in its potential. If the future depends on science, it also depends on the stories we tell. About Biotechnology Innovation Organization (BIO) BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services, worldwide. BIO members are at the forefront of researching and developing innovative biotechnologies across healthcare, agriculture, industry, and the environment. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. BIO is helping to drive a revolution that aims to cure patients, protect our climate, and nourish humanity. About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
Yahoo
3 days ago
- Business
- Yahoo
JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series
- Story Highlights Severity and Impact of MPS II, a Rare, Life-Threatening Lysosomal Storage Disorder - HYOGO, Japan, June 18, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured in The Next Frontier, a global branded film series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. The Next Frontier series explores how biotechnology can be used effectively to address urgent challenges the world faces. As part of the series, the JCR-sponsored film tells the story of a family affected by mucopolysaccharidosis type II (MPS II, or Hunter syndrome), a rare, progressive, life-threatening lysosomal storage disorder. "This film demonstrates the hardships and challenges that people living with MPS II face on a daily basis from the perspective of a family affected by this devastating and life-limiting disease," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "We are honored to participate in this important video series to shine a spotlight on MPS II and increase awareness worldwide about this debilitating rare disease for which patients desperately need new treatment options. This impactful story is a great illustration of how collaborating with patient communities drives progress. We are committed to supporting the MPS II patient community, and we look forward to advancing our investigational therapy for people living with MPS II." The Next Frontier series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection. The series debuted at the BIO International Convention, taking place from June 16-19, 2025. Watch the JCR film here, and view the full The Next Frontier series here. About The Next Frontier SeriesThe Next Frontier is a global branded film series presented by Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions, and it explores how biotechnology can be used effectively to address urgent challenges the world faces. The series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection and features the tools that help the public not just understand biotech but believe in its potential. If the future depends on science, it also depends on the stories we tell. About Biotechnology Innovation Organization (BIO)BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services, worldwide. BIO members are at the forefront of researching and developing innovative biotechnologies across healthcare, agriculture, industry, and the environment. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. BIO is helping to drive a revolution that aims to cure patients, protect our climate, and nourish humanity. About Mucopolysaccharidosis Type II (Hunter Syndrome)Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@
Cision Canada
4 days ago
- Science
- Cision Canada
Clarivate Unveils the 2025 Journal Citation Reports
LONDON, June 18, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2025 update to the Journal Citation Reports (JCR). This is the 50 th anniversary of the industry-leading annual reports, which provide a comprehensive overview of the world's leading and trusted academic journals, offering academic institutions, researchers, and publishers the ability to gauge journals' trustworthiness and impact. Only journals that have met the rigorous quality standards for inclusion in the Web of Science Core Collection are featured within the Journal Citation Reports, which ensures users can confidently rely on the information and descriptive data provided. The annual reports provide a rich array of publisher–neutral data, metrics, and analysis to enhance user understanding of journal performance, including the widely recognized Journal Impact Factor (JIF) and the Journal Citation Indicator. Key highlights for the 2025 release: The JCR includes data from a total of 22,249 journals across 254 categories Over 6,200 of these were published via gold open access Scholarly journals from 111 countries are recognized and receive a JIF, including 14,591 in the sciences and 7,559 in the social sciences, as well as 3,368 journals in the arts and humanities 618 journals receive a JIF for the first time This year's release excludes citations to and from retracted content when calculating the JIF numerator, ensuring that citations from retracted articles do not contribute to the numerical value of the JIF. However, retracted articles will still be included in the article count (JIF denominator), maintaining transparency and accountability. This policy affects 1% of journals. Dr. Nandita Quaderi, Senior Vice President & Editor-in-Chief, Web of Science, Clarivate, said: "We are proud to remain true to our heritage while adapting to changes in the scholarly landscape. As we celebrate the 50th anniversary of the JCR, we are embracing our founder Eugene Garfield's vision and looking to the future, reinforcing our dedication to maintaining the integrity of the scientific record and continuing our journey towards a more equitable, transparent and trustworthy scholarly ecosystem." Emmanuel Thiveaud, Senior Vice President, Research and Analytics, Academia & Government at Clarivate said: "We are excited to present the 2025 edition of the Journal Citation Reports, which continues to serve as a vital tool for the global research community. These valuable data and insights empower researchers and institutions to make informed decisions, fostering the advancement of knowledge and innovation." To explore all available data, metrics and analysis visit the Journal Citation Reports. For more detailed information on this year's changes, please see our blog.
Yahoo
06-06-2025
- Business
- Yahoo
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
06-06-2025
- Business
- Business Wire
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
